Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals' stock price has increased significantly in the last six months due to positive clinical trial data for tegoprubart, favorable regulatory progress including Orphan Drug designation, and financial results showing a narrower-than-expected Q4 2025 EPS loss. The company also has strategic collaborations with eGenesis, Inc. and NewcelX Ltd.

Eledon Pharmaceuticals exhibits some seasonal patterns in its stock performance, with May historically being the strongest month and June the weakest. However, the seasonal pattern has a poor consistency score, and demand is currently tied to clinical trial progress and regulatory approvals.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for severe conditions, targeting the CD40L pathway. Their lead product, tegoprubart, is being developed for kidney, islet cell, and liver transplantation, as well as ALS. The company is headquartered in Irvine, California.

Eledon Pharmaceuticals is based in Irvine, California, and its stock is listed on the NASDAQ in the United States. Additionally, its shares are traded on several European exchanges, indicating a broader international presence in terms of stock market accessibility.

Eledon Pharmaceuticals' brand reputation has been positively influenced by advancements in clinical development and regulatory achievements, including positive clinical data for tegoprubart, Orphan Drug designations, strategic collaborations, and positive analyst sentiment.

Eledon Pharmaceuticals has a mixed ownership structure, with institutional shareholders holding the largest portion, followed by hedge funds, retail investors, and insiders. Major institutional owners include BVF Partners L.P., The Vanguard Group, Inc., and BlackRock, Inc. Seth Loring Harrison is the largest individual shareholder.